Clinical Trial

PREcision meDICine in Treatment in CardioVascular Disease

Study acronym: PREDICT-CVD
Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Despite extensive modelling, it was not possible to develop a model that had sufficient accuracy and could be readily applied in a clinical trial.
Summary
The main goal of PREDICT-CVS is to demonstrate that a personalized, AI-derived biomarker-guided medication treatment algorithm that provides advice to the treating professional is superior to prevent clinical events and improve quality of life (QoL) when compared to patients receiving standard treatment of care. Participants will be randomized into two groups * Group 1 - Standard treatment Participant will receive the usual treatment for heart failure, based on current medical guidelines. * Group 2 - AI-supported treatment The professional will receive a personalized treatment plan generated by the AI program. This plan is based on medical information and biomarkers. The professional can choose whether or not to follow the AI's advice, reasons for not following the AI-based advice will be collected. Participants will visit the outpatient clinic at 1, 2, 3 and 9 months after being randomized.
Protocol Amendment History 2 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-04-18
notable Enrollment reduced: 430 -> 0 participants 2026-04-18
Trial Details
NCT Number NCT07369141
Lead Sponsor Maastricht University Medical Center
Collaborators: University Medical Center Groningen, Maastricht University
Conditions Chronic Heart Failure, Acute Decompensated Heart Failure
Start Date 2026-02
Primary Completion 2028-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-17